Pande Atul 4

What Happened
Atul Pande, a director of Immunovant, was granted two equity awards on April 7, 2026: 13,880 restricted stock units (RSUs) and 7,061 derivative option-based awards. Both grants were recorded at a $0.00 per-share acquisition price (standard for compensation awards), so no cash changed hands in this filing.

Key Details

• Transaction date: April 7, 2026; Form 4 filed April 9, 2026 (timely within the two-business-day reporting window).
• Awards: 13,880 RSUs (non‑derivative) and 7,061 option-based/derivative awards; reported price $0.00, total reported value $0 for both lines.
• Vesting: Both awards vest in full on April 1, 2027, subject to Pande’s continuous service through that date. RSUs can be deferred upon vesting under Rule 409A (per filing footnote).
• Shares owned after the transaction: Not specified in the filing excerpt.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax‑withholding, cashless exercise, or late‑filing flags noted in the filing.

Context
These grants are standard equity compensation for a board member and are contingent on continued service through the vesting date; they are not an immediate market purchase or sale. RSUs convert to common stock only upon vesting, and the option-based awards’ underlying shares also vest on April 1, 2027 — neither results in immediate proceeds unless subsequently exercised or sold. Such grants are common and should be interpreted as compensation rather than a direct insider buy/sell signal.